Page 206 - Read Online

Page 702 Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006

Availability of data and materials
Not applicable.

Financial support and sponsorship
This study was supported by the Biomedical Research Networking Center in Hepatic and Digestive Diseases
- CIBERehd (EHD15PI05/2016); the Health Research Fund, Institute of Health Carlos III, Spain (PI16/00598,
co-funded by the European Regional Development Fund/European Social Fund, "Investing in your
future"); the Spanish Ministry of Economy, Industry and Competitiveness (SAF2016-75197-R); the Regional
Government of Castile and Leon (SA063P17); and the AECC Scientific Foundation (2017/2020), Spain. MAP,
ASM and PSS were supported by a pre-doctoral contract by “Ministry of Education, Culture and Sports”,
Spain (BOE-A-2015-9456 and BOE-B-2017-72875). REE was supported by a pre-doctoral contract funded by
the “Junta de Castilla y León, Fondo Social Europeo” (EDU/574/2018).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
2. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
3. Yao S, Johnson C, Hu Q, Yan L, Liu B, et al. Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American
and European American populations. Oncotarget 2016;7:40491-9.
4. Witt-Kehati D, Fridkin A, Alaluf MB, Zemel R, Shlomai A. Inhibition of pMAPK14 overcomes resistance to sorafenib in hepatoma
cells with hepatitis b virus. Transl Oncol 2018;11:511-7.
5. EASL. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-
90.
7. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
8. Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol 2019;9:221-32.
9. Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma.
Liver Int 2019;39 Suppl 1:108-22.
10. Banales JM, Inarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, et al. Serum metabolites as diagnostic biomarkers for
cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology 2018;doi: 10.1002/hep.30319.
11. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, et al. Expert consensus document: cholangiocarcinoma: current
knowledge and future perspectives consensus statement from the european network for the study of cholangiocarcinoma (ENS-CCA).
Nat Rev Gastroenterol Hepatol 2016;13:261-80.
12. Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, et al. Chemoresistance and chemosensitization in cholangiocarcinoma.
Biochim Biophys Acta Mol Basis Dis 2018;1864:1444-53.
13. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, et al. HGVS recommendations for the description of sequence
variants: 2016 Update. Hum Mutat 2016;37:564-9.
14. Sprowl JA, Sparreboom A. Uptake carriers and oncology drug safety. Drug Metab Dispos 2014;42:611-22.
15. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib
and sorafenib-glucuronide. Clin Cancer Res 2013;19:1458-66.
16. Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet
2013;28:4-18.